🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

44 results for “Incyte” Clear

  1. Zelvina 25 mg hard capsules, Zelvina 10 mg hard capsules, Zelvina 15 mg hard capsules, Zelvina 5 mg hard capsules, Zelvina 20 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion

    Incyte Biosciences Distribution B.V.

    Diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  2. A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

    Incyte Biosciences Distribution B.V.

    Anaemia associated with myelofibrosis

    phase 2 other active

    1 trial

  3. A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression “(MAESTRA 1)”

    Incyte Biosciences Distribution B.V.

    Ovarian Cancer

    phase 2 other active

    1 trial

  4. Axatilimab (INCA034176)

    Incyte Biosciences Distribution B.V.

    Chronic Graft-Versus-Host Disease

    phase 2 small molecule active

    1 trial

  5. Axatilimab (INCA034176), PREDNISONE, METHYLPREDNISOLONE, Jakavi 5 mg tablets

    Incyte Biosciences Distribution B.V.

    chronic graft-versus-host disease

    phase 2 small molecule active

    1 trial

  6. INCAGN02385, Retifanlimab (INCMGA00012), INCAGN02390

    Incyte Biosciences Distribution B.V.

    In participants with PD-L1–positive and systemic therapy–naive R/M SCCHN.

    phase 2 small molecule active

    1 trial

  7. INCB000928, Placebo

    Incyte Biosciences Distribution B.V.

    Fibrodysplasia Ossificans Progressiva

    phase 2 small molecule active

    1 trial

  8. INCB099280, Adagrasib

    Incyte Biosciences Distribution B.V.

    Advanced Solid Tumors Harboring a KRASG12C Mutation

    phase 2 small molecule active

    1 trial

  9. Iclusig 15 mg film-coated tablets, Iclusig 45 mg film-coated tablets, Ponatinib, Iclusig 15 mg film-coated tablets, Iclusig 15 mg film-coated tablets, Iclusig 30 mg film-coated tablets., Ponatinib, Iclusig 45 mg film-coated tablets, Ponatinib

    Incyte Biosciences Distribution B.V.

    Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors

    phase 2 small molecule active

    1 trial

  10. Jakavi 5 mg tablets, Jakavi 15 mg tablets

    Incyte Biosciences Distribution B.V.

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  11. Pemazyre 4.5 mg tablets, INCAGN02385, INCAGN02390, Retifanlimab (INCMGA00012)

    Incyte Biosciences Distribution B.V.

    Endometrial cancer, Endometrial cancer

    phase 2 small molecule active

    1 trial

  12. Povorcitinib, Placebo, Povorcitinib, Povorcitinib

    Incyte Biosciences Distribution B.V.

    Treatment of patients with inadequately controlled moderate to severe asthma

    phase 2 small molecule active

    1 trial

  13. Zelvina 10 mg hard capsules, Zelvina 25 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion, Zelvina 5 mg hard capsules

    Incyte Biosciences Distribution B.V.

    Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  14. A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors

    Incyte Biosciences Distribution B.V.

    Advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  15. A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms.

    Incyte Biosciences Distribution B.V.

    Myeloproliferative Neoplasms

    phase 1 other active

    1 trial

  16. A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors with KRAS G12D Mutation

    Incyte Biosciences Distribution B.V.

    Advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  17. A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

    Incyte Biosciences Distribution B.V.

    Treatment of participants with MF, MDS, ET, or MDS/MPN

    phase 1 other active

    1 trial

  18. A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

    Incyte Biosciences Distribution B.V.

    Advanced malignancies.

    phase 1 other active

    1 trial

  19. A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia

    Incyte Biosciences Distribution B.V.

    Myeloproliferative Neoplasms

    phase 1 other active

    1 trial

  20. INCB099280, YERVOY 5 mg/ml concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion

    Incyte Biosciences Distribution B.V.

    Solid tumor

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources